MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why FULC Stock advanced +0.53% Today — RQD Quant Desk Flash
$3.77 +0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.77
Fulcrum Therapeutics Inc. (FULC) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $288.0M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.77 (-0.09%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FULC)Realized 20D OHLCV Swing Band: ±3.9%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY FULC SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 48.8 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.77-3.2% Next Q
32
Q2 (-2Q)Grade E$3.65+0.8% Next Q
35
Q3 (-1Q)Grade E$3.68+2.4% Next Q
37
CurrentGrade D-$3.77-7.4% Hist 90D α
40
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FULC Turnaround Squeeze
While FULC currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($3.96) forces dealer call-delta covering toward $16.53.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FULC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FULC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FULC Stock advanced +0.53% Today — RQD Quant Desk Flash
Fulcrum Therapeutics Inc. (FULC) advanced +0.53% to $3.77, trading at 7% of its 52-week range ($2.83 – $15.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($2.83 – $15.74) with RSI-14 at 48.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±3.9% around $3.77 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live FULC Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FULC)
- ✓Walkthrough of FULC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FULC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.12%▲ RESISTANCE BREAKOUT
2026-10-30O $3.74H $3.77L $3.68C $3.77VOL 933.2K
RES: $3.75SUP: $3.64SMA50: $3.76SMA200: $5.86
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FULC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on FULC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FULC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FULC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FULC)
Health Care Rank #641 of 1016
⚔️ VOGX vs FULC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FULC vs. VOGX, GLSI, RCKT, LRMR)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Fulcrum Therapeutics Inc. (FULC) ranks #641 by composite RQD confidence (40/100, grade D-) and #524 by equity capitalization ($288.0M). Within this direct 5-issuer industry benchmark cohort, FULC leads on earnings valuation at N/A trailing P/E, while FULC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with FULC at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FULC
ACTIVE
Fulcrum Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +0.53% | $288.0M | Benchmark Subject |
| VOGX Vogenx Inc | D+ | 56/100 | — | — | — | +5.29% | $295.9M | /vogx-vs-fulc → |
| GLSI Greenwich LifeSciences Inc. | D- | 41/100 | — | — | -35.0% | +3.77% | $278.9M | /glsi-vs-fulc → |
| RCKT Rocket Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.55% | $278.8M | /rckt-vs-fulc → |
| LRMR Larimar Therapeutics Inc. | D | 50/100 | — | — | -35.0% | +5.12% | $277.4M | /lrmr-vs-fulc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680581In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulcrum Therapeutics Inc. (FULC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.9M, operating cash flow of -$60.1M, and free cash flow of -$60.4M (-2319.0% YoY). On the balance sheet, FULC closed FY2025 with $366.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$74.9M | -$60.1M | -$60.4M | $366.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$9.7M | -$2.2M | -$2.5M | $260.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$97.3M | -$91.0M | -$91.0M | — | — |
3. FULC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FULC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Fulcrum Therapeutics Inc. (NASDAQ: FULC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.77 (+0.53% 1D, market cap $288.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FULC ranks #641 in composite RQD confidence.
How does FULC compare to VOGX and GLSI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FULC carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VOGX (Vogenx Inc) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $295.9M) and GLSI (Greenwich LifeSciences Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $278.9M). Among the 5-stock peer group, FULC leads on earnings multiple (N/A) while FULC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FULC?
Per FULC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680581), Fulcrum Therapeutics Inc. generated $0 in revenue, -$74.9M in net income, and -$60.4M in free cash flow against $366.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FULC trading relative to its 50-day, 200-day, and 52-week technical levels?
FULC last traded at $3.77 (+0.53% on volume of 1,621,239 shares), positioning the stock +0.27% above its 50-day simple moving average ($3.76) and -35.67% below its 200-day simple moving average ($5.86). Across its 52-week range of $2.83 to $15.74, FULC sits at the 7.3% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±3.9% ($3.62 to $3.92).
FULC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FULC stock moving today?
Why FULC Stock advanced +0.53% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.